Seasonique

Referenzen

Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruation-related symptoms? Contraception. 2006;73(5):537-541.

den Tonkelaar I, Oddens BJ Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59(6):357-362.

Fauser BCJM and van Heusden AM. Manipulation of human ovarian function: Physiological concepts and clinical consequences*. Endocrine Reviews. 1997;18:71-106.

Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71-77.

Schlaff WD, Lynch AM, Hughes HD, et al. Manipulation of the pill-free interval in oral contraceptive pill users: The effect on follicular suppression. Obstet Gynecol. 2004;190:943-951.

Endrikat J, Gerlinger C, Plettig K, et al. A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual during low-dose oral contraceptive use. Gynecol Endocrinol. 2003;17:107-114.

Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-266

Reape KZ, DiLiberti CE, Hendy CH, Volpe EJ. Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive. Contraception. 2008; 77:34-39

Vandever et al. Contraception. 2008;77:162-170.

Data on file. DR-PSE-305 A randomized, multicenter, double-blind study to evaluate the efficacy of an extended cycle combination oral contraceptive, DP3-84/10, which utilizes ethinyl estradiol during the usual hormone-free interval, compared to conventional oral contraceptive therapy for the treatment of cyclic pelvic pain in women. Teva Women’s Health Research, Inc. 2009.

Davis MG, Reape KZ, Hait H. A look at the long-term safety of an extended-regimen OC. J Fam Pract. 2010;59(5):E9-E13.

DiLiberti CE, et al. Contraception. 2011;83:55-61.

Anderson FD, Feldman R, Reape KZ. Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo. Contraception. 2008;77(2):91-96.

Österreichischer Verhütungsreport 2012 www.verhuetungsreport.at

Einstellungen der Frauen zu Körper und Sexualität Online-Befragung des Salzburger Frauengesundheitszentrum ISIS, 2012, http://www.frauengesundheitszentrum-isis.at/images/downloads___off/Langfassung%20Sex%20u%20Koerper.pdf

Ferrero S, Abbamonte LH, Giordano M, et al. What is the desired menstrual frequency of women without menstruation-related symptoms? Contraception. 2006;73(5):537-541.

den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception. 1999;59(6):357-362.

Snow R, Hardy E, Kneuper E, Hebling EM, Hall G. Women’s responses to menses and nonbleeding intervals in the USA, Brazil and Germany. Contraception. 2007;76(1):23-29.

Edelman A, Gallo MF, Nichols MD, Jensen JT, Schulz KF, Grimes DA. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum Reprod. 2006;21(3):573-578.

Sulak PJ, et al. Obstet Gynecol. 2000;95:261-266.

Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77(3):162-170.

Szarewski A, Mansour D, Shulman LP 50 years of “The Pill”: celebrating a golden anniversary. J Fam Plann Reprod Health Care. 2010;36(4):231-238

Fachinformation Seasonique 150 Mikrogramm/30 Mikrogramm + 10 Mikorgramm Filmtabletten. Stand 01/2015

Anderson FD, Gibbons W, Portman D. Safety and effcacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol. Contraception. 2006; 73(3): 229-234

Davis MG, Reape KZ, Hait H. A look at the long-term safety of an extended-regimen OC. J Fam Pract. 2010;59(5):E9-E13.

Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks—CHMO endorses PRAC recommendation [news release]. London, UK: European Medicines Agency; November 22, 2013. http:// www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001969.jsp&mid=WC0b01ac058004d5c1. Accessed June 2, 2014

ratiopharm Arzneimittel Vertriebs-GmbH
Albert-Schweitzer-Gasse 3
1140 Wien

Medical: Dr. Petra Olf, petra.olf@tevapharm.at; +43 1 97007 355
Marketing: Michaela Leithner, MA, mleithner@ratiopharm.at; +43 1 97007 230

bereitgestellt von medONLINE.at / ein Service der Medizin Medien Austria GmbH